Prescription Dermatology
Bimekizumab (BIMZELX)
Dual IL-17A/IL-17F inhibitor for plaque psoriasis
Duration
subcutaneous (導入後は維持間隔投与)
Downtime
なし
Sessions
定期投与 (製品ラベル準拠)
About This Treatment
Bimekizumab is a monoclonal antibody that neutralizes both IL-17A and IL-17F, showing high skin-clearance rates in moderate-to-severe plaque psoriasis.
Mechanism of Action
It suppresses IL-17A/F signaling, reducing keratinocyte hyperproliferation and downstream inflammatory cascades in psoriasis.
Indications
General indication (see detailed description)
Expected Results
Phase 3 trials demonstrated high PASI90/100 rates with sustained efficacy in longer-term analyses.
Clinical Evidence
Reich K, et al. (2021)
BE VIVID phase 3 trial: bimekizumab vs ustekinumab/placebo. Lancet
Clinical improvement was reported in this study (see original paper for details).
Merola JF, et al. (2022)
Pooled phase 2/3 safety analysis of bimekizumab. JAMA Dermatol
Clinical improvement was reported in this study (see original paper for details).
U.S. FDA (2024)
BIMZELX prescribing information. FDA label
Clinical improvement was reported in this study (see original paper for details).
Risks & Side Effects
Upper respiratory infections, oral/genital candidiasis, and injection-site reactions are common. Monitor for infection and potential IBD exacerbation.
Interested in this treatment?
Start with an AI skin analysis to check your current skin condition